Adrian Hernandez gives background information about iron metabolism and discusses results from outcome trials on iron deficiency in HF.

This study introduced an air pollution score to investigate the association between long-term joint exposure to various ambient air pollutants and risk of incident HF in the UK Biobank.

Subgroup analyses from DAPA-HF and EMPEROR-Reduced evaluated the effects of dapagliflozin and empagliflozin on CV and kidney outcomes according to baseline kidney function in patients with HFrEF.

This exploratory analysis from DAPA-HF showed that dapagliflozin, compared to placebo, reduced new-onset T2DM in patients with HFrEF without diabetes at baseline.

The FDA has granted expansion of the label of sacubitril/valsartan for the treatment of patients with chronic HF, including both HFrEF and HFpEF. The label includes the statement that clinical judgment should be used in deciding whom to treat.

John McMurray and Milton Packer proposed a new algorithm to achieve treatment with a beta-blocker, SGLT2i, ARNI and MRA within 4 weeks in patients with HFrEF.

This subanalysis of PARAGON-HF showed that efficacy outcomes with sacubitril/valsartan compared to valsartan were independent of MRA use in patients with HFpEF.

A risk score based on elevated levels of hs-cTnT, NT-proBNP, and hs-CRP, and presence of left ventricular hypertrophy can stratify incident HF risk in patients with dysglycemia without CVD.

A subanalysis of EMPEROR-Reduced demonstrated that sacubitril/valsartan treatment in patients with HFrEF did not affect risk reducing effects of empagliflozin on HF and kidney events.

The 2021 update to the 2017 heart failure ECDP was just published. Prof. Januzzi explains the contribution of this document in addition to the guidelines and shares the most important updates.

The soluble guanylate cyclase (sGC) stimulator vericiguat has been approved by the FDA to reduce risk of CV death and HF hospitalization following hospitalization for HF or need for outpatient IV diuretics in HFrEF patients.

The ACC Expert Consensus Decision Pathway (ECDP) for optimization of HFrEF treatment provides practical guidance for physicians in managing patients with HFrEF. The 2017 ECDP has now been updated.